Nanoparticle albumin-bound paclitaxel for metastatic breast cancer

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 7768-7771

  Harries, Mark ^a   Ellis, Paul ^a   Harper, Peter ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALCOHOL; ANTHRACYCLINE; ANTIHISTAMINIC AGENT; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NANOPARTICLE; PACLITAXEL; POLYSORBATE 80; RICINOMACROGOL; STEROID; TAXANE DERIVATIVE; TRASTUZUMAB; ALBUMINOID; ANTINEOPLASTIC AGENT; NANOMATERIAL;

ADJUVANT THERAPY; ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; EDITORIAL; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GENE OVEREXPRESSION; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; LACRIMATION; LEUKEMIA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; FEMALE; METASTASIS; NOTE;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; HUMANS; NANOSTRUCTURES; PACLITAXEL;

EID: 32944466762     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.002     Document Type: Editorial

References (33)

1. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995
2. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
3. Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
4. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
5. ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532, 1994
6. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999
7. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724-733, 2000
8. Albain K, Nag S, Calderillo-Ruiz G: Global phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc Am Soc Clin Oncol 22:5s, 2004 (abstr 510)
9. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
10. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes form adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
11. Mamounas E, Bryant J, Fehrenbacher L, et al: Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer. Results from NSABP B-28. Proc Am Soc Clin Oncol 22:4, 2003 (abstr 12)
12. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
13. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
14. Romond EH, Perez EA, Bryant J, et al: Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer: Combined analysis of NSABP-B31/NCCTG-N9831, Advances in monoclonal antibody therapy for breast cancer. American Society of Clinical Oncology Scientific Symposium, Orlando, FL, May 13-17, 2005
15. Piccart M: First results of the HERA trial: Advances in monoclonal antibody therapy for breast cancer. American Society of Clinical Oncology Scientific Symposium, Orlando, FL, May 13-17, 2005
16. Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from taxol. J Clin Oncol 8:1263-1268, 1990
17. Bookman MA, Kloth DD, Kover PE, et al: Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8:611-614, 1997
18. Markman M, Kennedy A, Webster K, et al: An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 125:427-429, 1999
19. Micha JP, Rettenmaier MA, Dillman R, et al: Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 69:122-124, 1998
20. Parikh B, Khanolkar S, Advani SH, et al: Safety profile of single-dose dexamethasone premedication for paclitaxel. J Clin Oncol 14:2189-2190, 1996
21. Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223, 2001
22. Tabernero J, Climent MA, Lluch A, et al: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365, 2004
23. Wolff AC, Donehower RC, Carducci MK, et al: Phase I study of docosahexaenoic acid-paclitaxel: A taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9:3589-3597, 2003
24. Kim TY, Kim DW, Chung JY, et al: Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708-3716, 2004
25. Hidalgo M, Aylesworth C, Hammond LA, et al: Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 19:2493-2503, 2001
26. Sessa C, Cuvier C, Caldiera S, et al: Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 13:1140-1150, 2002
27. Kurata T, Shimada Y, Tamura T, et al: Phase I and pharmacokinetic study of a new taxoid, RPR 109881 A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 18:3164-3171, 2000
28. Sparreboom A, Scripture CD, Trieu V, et al: Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11:4136-4143, 2005
29. Ibrahim NK, Desai N, Legha S, et al: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044, 2002
30. Ibrahim NK, Samuels B, Page R, et al: Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019-6026, 2005
31. Gradishar WJ, Tjulandin S, Davidson N, et al: Superior efficacy of nanoparticle albumin-bound paclitaxel (Abraxane, ABI-007) compared with cremophor-based paclitaxel (Taxol) in women with metastatic breast cancer: Results of a phase III trial. J Clin Oncol 23:7794-7803, 2005
32. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 22:2061-2068, 2004
33. Jones S, Erban J, Overemoyer B: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551, 2005